Neoadjuvant chemotherapy for early breast cancer
We congratulate the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) on - their important meta-analysis.1 Neoadjuvant chemotherapy (NACT) has become an important - tool and strategy for patients with breast cancer. Although NACT was traditionally - used in patients with locally advan...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) Editorial |
| Language: | English |
| Published: |
28 February 2018
|
| In: |
The lancet. Oncology
Year: 2018, Volume: 19, Issue: 3, Pages: e129 |
| ISSN: | 1474-5488 |
| DOI: | 10.1016/S1470-2045(18)30118-9 |
| Online Access: | Verlag, Volltext: https://doi.org/10.1016/S1470-2045(18)30118-9 Verlag: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30118-9/abstract 
|
| Author Notes: | David Krug, Sibylle Loibl |
| Summary: | We congratulate the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) on - their important meta-analysis.1 Neoadjuvant chemotherapy (NACT) has become an important - tool and strategy for patients with breast cancer. Although NACT was traditionally - used in patients with locally advanced breast cancer, with the aim of downstaging - and achieving operability, monitoring treatment response for prognostic purposes and - for risk stratification has become routine in current practice. |
|---|---|
| Item Description: | Gesehen am 13.11.2019 |
| Physical Description: | Online Resource |
| ISSN: | 1474-5488 |
| DOI: | 10.1016/S1470-2045(18)30118-9 |